Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension

Journal of Human Hypertension

Volumn 24, Issue 11, 2010, Pages 730-738

  Chrysant, S G ^a   Lee, J ^b   Melino, M ^b   Karki, S ^b   Heyrman, R ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

Angiotensin receptor blocker; calcium channel blocker; elderly; obesity; race; type II diabetes

Indexed keywords

AMLODIPINE; OLMESARTAN; PLACEBO;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MONOTHERAPY; RACE DIFFERENCE; SYSTOLIC BLOOD PRESSURE; VERTIGO;

AFRICAN AMERICANS; AGE FACTORS; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY MASS INDEX; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; OBESITY; RISK ASSESSMENT; RISK FACTORS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASODILATOR AGENTS;

EID: 77958061226     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.5     Document Type: Article

References (20)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187. (Pubitemid 46924065)
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
4. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163: 525-541.
5. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-e146.
6. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002; 25: 134-147.
7. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49: 69-75.
8. Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 2007; 167: 2431-2436.
9. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005; 46: 200-204.
10. Pessina AC. Target organs of individuals with diabetes caught between arterial stiffness and damage to the microcirculation. J Hypertens Suppl 2007; 25(Suppl 1): S13-S18.
11. Watson KE. Cardiovascular risk reduction among African Americans: a call to action. J Natl Med Assoc 2008; 100: 18-26.
12. Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A. Reninangiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26: 831-843.
13. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31(Suppl 1): S12-S54.
14. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep 2002; 4: 479-482.
15. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich) 2003; 5: 330-335.
16. Volpe M. Hypertension therapy: mixing, matching, and meeting targets. Adv Ther 2004; 21: 107-122.
17. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
18. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlof B, Velazquez EJ et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press 2008; 17: 7-17.
19. Chrysant S, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587-604.
20. McInnes GT. How important is optimal blood pressure control? Clin Ther 2004; 26(Suppl A): A3-A11.